Abstract: Methods, systems, and storage media for computing engagement scores for record objects are disclosed. Exemplary implementations may: access data of a record object; identify a plurality of electronic activities linked with the record object; determining a field-value pair of the record object corresponding to a first time instance; determining a length of time between the first time instance and a second time instance; determining a first count of electronic activities included in the plurality of electronic activities generated between the first time instance and the second time instance; determining a second count based on the plurality of electronic activities generated between the first time instance and the second time instance; computing an engagement score for the record object based on the first count, the second count, and the length of time; and storing, in one or more data structures, an association between the engagement score and the record object.

Abstract: The invention discloses a method for preparing chitosan and a derivative nanofiber thereof by mechanical means. The method comprises: firstly pre-treating a chitosan fiber or a chitosan derivative fiber material (referred to as chitosan fiber) of a suitable length with water or alkali or acid of an appropriate concentration added, then refining or beating the treated fiber (preferably using a beating device in a beating and papermaking process) to obtain a micro-sized chitosan fiber, and finally homogenizing the micro-sized chitosan fiber under a high pressure to obtain a chitosan nanofiber. According to an electron microscope image, the obtained chitosan nanofiber reaches a nano-level. The method is simple in operation and convenient for industrial production, and the obtained chitosan nanofiber with a new topology has broad application prospects in biomedicine, daily chemical engineering and special materials.

Abstract: Disclosed is a pharmaceutical composition, comprising a first component and a second component, wherein the first component is selected from at least one of a farnesoid X receptor agonist and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, an ester and a solvate thereof; and the second component is selected from at least one of a NPC1L1 receptor inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, an ester and a solvate thereof. The composition can be used in preventing and/or treating non-alcoholic fatty liver disease, diabetes or cardiovascular disease.